

Paola Queirolo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7141786/publications.pdf>

Version: 2024-02-01

179
papers

11,886
citations

38742

50
h-index

30087

103
g-index

192
all docs

192
docs citations

192
times ranked

14219
citing authors

#	ARTICLE	IF	CITATIONS
1	Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1824-1835.	27.0	1,752
2	MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. <i>Lancet Oncology</i> , The, 2013, 14, 249-256.	10.7	587
3	Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. <i>Annals of Oncology</i> , 2010, 21, 1712-1717.	1.2	468
4	Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 435-445.	10.7	399
5	Vaccination of Metastatic Melanoma Patients With Autologous Tumor-Derived Heat Shock Protein gp96-Peptide Complexes: Clinical and Immunologic Findings. <i>Journal of Clinical Oncology</i> , 2002, 20, 4169-4180.	1.6	361
6	Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. <i>Annals of Oncology</i> , 2016, 27, 732-738.	1.2	321
7	Rare missense variants in POT1 predispose to familial cutaneous malignant melanoma. <i>Nature Genetics</i> , 2014, 46, 482-486.	21.4	283
8	Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. <i>Lancet Oncology</i> , The, 2012, 13, 879-886.	10.7	273
9	Melanoma Cells Inhibit Natural Killer Cell Function by Modulating the Expression of Activating Receptors and Cytolytic Activity. <i>Cancer Research</i> , 2012, 72, 1407-1415.	0.9	267
10	Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 20847-20852.	7.1	264
11	Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. <i>Nature Medicine</i> , 2019, 25, 941-946.	30.7	256
12	Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study. <i>Lancet Oncology</i> , The, 2014, 15, 436-444.	10.7	242
13	Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 675-683.	4.2	230
14	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 643-654.	10.7	224
15	Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 510-520.	10.7	183
16	Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma.. <i>Journal of Clinical Oncology</i> , 1994, 12, 806-811.	1.6	156
17	Clinical experience with ipilimumab 3Âmg/kg: real-world efficacy and safety data from an expanded access programme cohort. <i>Journal of Translational Medicine</i> , 2014, 12, 116.	4.4	149
18	Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma. <i>European Journal of Cancer</i> , 2014, 50, 121-127.	2.8	149

#	ARTICLE	IF	CITATIONS
19	Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility. <i>Nature Genetics</i> , 2020, 52, 494-504.	21.4	138
20	The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF- α production. <i>Journal of Translational Medicine</i> , 2013, 11, 108.	4.4	136
21	Natural killer cells kill human melanoma cells with characteristics of cancer stem cells. <i>International Immunology</i> , 2009, 21, 793-801.	4.0	134
22	BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies. <i>OncoTargets and Therapy</i> , 2015, 8, 157.	2.0	134
23	Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial. <i>Annals of Oncology</i> , 2017, 28, 1380-1387.	1.2	134
24	Uveal melanoma. <i>Cancer Treatment Reviews</i> , 2012, 38, 549-553.	7.7	120
25	Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma. <i>Annals of Oncology</i> , 2013, 24, 2911-2915.	1.2	119
26	Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 41-48.	4.2	118
27	Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study. <i>Annals of Oncology</i> , 2015, 26, 798-803.	1.2	118
28	KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma. , 2020, 8, e001806.		110
29	Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma. <i>Oncotarget</i> , 2014, 5, 10206-10221.	1.8	104
30	Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. <i>Journal of Neuro-Oncology</i> , 2014, 118, 109-116.	2.9	103
31	Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon- γ in metastatic melanoma. <i>Annals of Oncology</i> , 2006, 17, 571-577.	1.2	101
32	Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014, 33, 30.	8.6	97
33	Melanoma cells become resistant to NK cell-mediated killing when exposed to NK cell numbers compatible with NK cell infiltration in the tumor. <i>European Journal of Immunology</i> , 2012, 42, 1833-1842.	2.9	94
34	Identification, genetic testing, and management of hereditary melanoma. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 77-90.	5.9	93
35	Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program. <i>Cancer Investigation</i> , 2014, 32, 144-149.	1.3	90
36	Radiation-associated angiosarcoma: Diagnostic and therapeutic implications—Two case reports and a review of the literature. <i>Cancer</i> , 1996, 77, 2496-2502.	4.1	83

#	ARTICLE	IF	CITATIONS
37	Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index. <i>European Journal of Cancer</i> , 2021, 142, 18-28.	2.8	81
38	Prevalence of the <i>318</i> <i>MITF</i> germline mutation in Italian melanoma patients: associations with histological subtypes and family cancer history. <i>Pigment Cell and Melanoma Research</i> , 2013, 26, 259-262.	3.3	80
39	Characterization of ligurian melanoma families and risk of occurrence of other neoplasia. , 1999, 83, 441-448.		78
40	Current status and perspectives in immunotherapy for metastatic melanoma. <i>Oncotarget</i> , 2018, 9, 12452-12470.	1.8	73
41	Survival of patients with metastatic melanoma and brain metastases in the era of MAP-kinase inhibitors and immunologic checkpoint blockade antibodies: A systematic review. <i>Cancer Treatment Reviews</i> , 2016, 45, 38-45.	7.7	71
42	Granulocyte-macrophage colony-stimulating factor (GM-CSF) allows acceleration and dose intensity increase of CEF chemotherapy: a randomised study in patients with advanced breast cancer. <i>British Journal of Cancer</i> , 1994, 69, 385-391.	6.4	70
43	<i>CDKN2A</i> is the main susceptibility gene in Italian pancreatic cancer families. <i>Journal of Medical Genetics</i> , 2012, 49, 164-170.	3.2	64
44	<i>Mda-9/Syntenin</i> Is Expressed in Uveal Melanoma and Correlates with Metastatic Progression. <i>PLoS ONE</i> , 2012, 7, e29989.	2.5	64
45	Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma. <i>Cancer Treatment Reviews</i> , 2015, 41, 519-526.	7.7	63
46	Inherited variants in the <i>MC1R</i> gene and survival from cutaneous melanoma: a BioGenoMEL study. <i>Pigment Cell and Melanoma Research</i> , 2012, 25, 384-394.	3.3	61
47	Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 97-107.	4.2	61
48	High prevalence of the G101W germline mutation in the <i>CDKN2A</i> (<i>P16ink4a</i>) gene in 62 Italian malignant melanoma families. <i>American Journal of Medical Genetics Part A</i> , 2002, 107, 214-221.	2.4	60
49	Bevacizumab plus Fotemustine as First-line Treatment in Metastatic Melanoma Patients: Clinical Activity and Modulation of Angiogenesis and Lymphangiogenesis Factors. <i>Clinical Cancer Research</i> , 2010, 16, 5862-5872.	7.0	56
50	Association of CTLA-4 Polymorphisms with Improved Overall Survival in Melanoma Patients Treated with CTLA-4 Blockade: A Pilot Study. <i>Cancer Investigation</i> , 2013, 31, 336-345.	1.3	55
51	Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy. <i>British Journal of Cancer</i> , 2014, 110, 1721-1726.	6.4	53
52	Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis. <i>BMJ, The</i> , 2021, 375, e066381.	6.0	53
53	Effect of Age on Melanoma Risk, Prognosis and Treatment Response. <i>Acta Dermato-Venereologica</i> , 2018, 98, 624-629.	1.3	52
54	Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma. <i>European Journal of Cancer</i> , 2021, 157, 250-258.	2.8	52

#	ARTICLE	IF	CITATIONS
55	Functional analysis of CDKN2A/p16INK4a 5'UTR variants predisposing to melanoma. <i>Human Molecular Genetics</i> , 2010, 19, 1479-1491.	2.9	51
56	Electrochemotherapy for the management of cutaneous and subcutaneous metastasis: A series of 39 patients treated with palliative intent. <i>Journal of Surgical Oncology</i> , 2014, 109, 270-274.	1.7	51
57	The density and spatial tissue distribution of CD8+ and CD163+ immune cells predict response and outcome in melanoma patients receiving MAPK inhibitors. , 2019, 7, 308.		51
58	Potential Role of Soluble c-Met as a New Candidate Biomarker of Metastatic Uveal Melanoma. <i>JAMA Ophthalmology</i> , 2015, 133, 1013.	2.5	48
59	CDKN2A mutations and MC1R variants in Italian patients with single or multiple primary melanoma. <i>Pigment Cell and Melanoma Research</i> , 2008, 21, 700-709.	3.3	46
60	Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. , 2021, 9, e001931.		46
61	INK4/ARF germline alterations in pancreatic cancer patients. <i>Annals of Oncology</i> , 2004, 15, 70-78.	1.2	45
62	Clinical genetic testing for familial melanoma in Italy: A cooperative study. <i>Journal of the American Academy of Dermatology</i> , 2009, 61, 775-782.	1.2	45
63	Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study. <i>European Journal of Cancer</i> , 2020, 134, 19-28.	2.8	45
64	Upcoming strategies for the treatment of metastatic melanoma. <i>Archives of Dermatological Research</i> , 2012, 304, 177-184.	1.9	44
65	Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion. <i>Clinical Cancer Research</i> , 2021, 27, 4311-4324.	7.0	44
66	Impact of E27X, a novel CDKN2A germ line mutation, on p16 and p14ARF expression in Italian melanoma families displaying pancreatic cancer and neuroblastoma. <i>Human Molecular Genetics</i> , 2006, 15, 2682-2689.	2.9	41
67	The adjuvant treatment revolution for high-risk melanoma patients. <i>Seminars in Cancer Biology</i> , 2019, 59, 283-289.	9.6	40
68	Sex-based differences in response to anti-PD-1 or PD-L1 treatment in patients with non-small-cell lung cancer expressing high PD-L1 levels. A systematic review and meta-analysis of randomized clinical trials. <i>ESMO Open</i> , 2021, 6, 100251.	4.5	39
69	Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9522-9522.	1.6	37
70	Susceptibility of Human Melanoma Cells to Autologous Natural Killer (NK) Cell Killing: HLA-Related Effector Mechanisms and Role of Unlicensed NK Cells. <i>PLoS ONE</i> , 2009, 4, e8132.	2.5	36
71	BRAF plus MEK-targeted drugs: a new standard of treatment for BRAF-mutant advanced melanoma. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 35-42.	5.9	35
72	Heterogeneity and frequency of BRAF mutations in primary melanoma: Comparison between molecular methods and immunohistochemistry. <i>Oncotarget</i> , 2017, 8, 8069-8082.	1.8	34

#	ARTICLE	IF	CITATIONS
73	<i><sc>MC</sc>1R</i> variation and melanoma risk in relation to host/clinical and environmental factors in <i><sc>CDKN</sc>2A</i> positive and negative melanoma patients. <i>Experimental Dermatology</i> , 2012, 21, 718-720.	2.9	33
74	Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline <i><sc>CDKN2A</sc></i> mutations. <i>Journal of Medical Genetics</i> , 2020, 57, 316-321.	3.2	33
75	Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 325-332.	1.2	32
76	Electrochemotherapy for the management of melanoma skin metastasis: a review of the literature and possible combinations with immunotherapy. <i>Archives of Dermatological Research</i> , 2014, 306, 521-526.	1.9	31
77	Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF V600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis. <i>European Journal of Cancer</i> , 2017, 79, 176-184.	2.8	31
78	Vitamin D in melanoma: Controversies and potential role in combination with immune check-point inhibitors. <i>Cancer Treatment Reviews</i> , 2018, 69, 21-28.	7.7	31
79	Treatment of metastatic uveal melanoma with intravenous fotemustine. <i>Melanoma Research</i> , 2013, 23, 196-198.	1.2	30
80	Sun exposure and melanoma prognostic factors. <i>Oncology Letters</i> , 2016, 11, 2706-2714.	1.8	29
81	Randomized cooperative study of perioperative chemotherapy in breast cancer.. <i>Journal of Clinical Oncology</i> , 1995, 13, 2712-2721.	1.6	28
82	Concurrent vs Sequential Adjuvant Chemotherapy and Hormone Therapy in Breast Cancer: A Multicenter Randomized Phase III Trial. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1529-1539.	6.3	27
83	Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study. <i>Frontiers in Immunology</i> , 2017, 8, 386.	4.8	27
84	Early onset may predict G101W CDKN2A founder mutation carrier status in Ligurian melanoma patients. <i>Melanoma Research</i> , 2004, 14, 443-448.	1.2	26
85	The cost of unresectable stage III or stage IV melanoma in Italy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2012, 31, 91.	8.6	25
86	<sc>ADAM</sc>10 correlates with uveal melanoma metastasis and promotes in vitro invasion. <i>Pigment Cell and Melanoma Research</i> , 2014, 27, 1138-1148.	3.3	25
87	Discrepant alterations in main candidate genes among multiple primary melanomas. <i>Journal of Translational Medicine</i> , 2014, 12, 117.	4.4	24
88	Multiple rare variants in high-risk pancreatic cancer-related genes may increase risk for pancreatic cancer in a subset of patients with and without germline CDKN2A mutations. <i>Human Genetics</i> , 2016, 135, 1241-1249.	3.8	24
89	Sentinel lymph node biopsy in patients with Stage I/II melanoma: Clinical experience and literature review. <i>Journal of Surgical Oncology</i> , 2004, 85, 133-140.	1.7	23
90	Clinical experience with ipilimumab 10Âmg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013, 32, 82.	8.6	23

#	ARTICLE	IF	CITATIONS
91	Skin signs resembling vascular acrosyndromes during the COVID-19 outbreak in Italy. <i>Clinical and Experimental Dermatology</i> , 2020, 45, 757-758.	1.3	23
92	The treatment of melanoma brain metastases before the advent of targeted therapies. <i>Melanoma Research</i> , 2014, 24, 61-67.	1.2	22
93	Binimetinib for the treatment of NRAS-mutant melanoma. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 985-990.	2.4	21
94	LBA3 Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the KEYNOTE-716 double-blind phase III trial. <i>Annals of Oncology</i> , 2021, 32, S1314-S1315.	1.2	21
95	Targeted therapies in melanoma. <i>Cancer Treatment Reviews</i> , 2006, 32, 524-531.	7.7	20
96	CDKN2A and MC1R analysis in amelanotic and pigmented melanoma. <i>Melanoma Research</i> , 2009, 19, 142-145.	1.2	20
97	No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) Study. <i>Cancers</i> , 2021, 13, 475.	3.7	20
98	HO-1 downregulation favors BRAF V600 melanoma cell death induced by Vemurafenib/PLX4032 and increases NK recognition. <i>International Journal of Cancer</i> , 2020, 146, 1950-1962.	5.1	19
99	Insights into Genetic Susceptibility to Melanoma by Gene Panel Testing: Potential Pathogenic Variants in ACD, ATM, BAP1, and POT1. <i>Cancers</i> , 2020, 12, 1007.	3.7	19
100	Immunotherapy for the Treatment of Cutaneous Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 733917.	2.8	19
101	Adoptive Immunotherapy With Tumor-Infiltrating Lymphocytes and Subcutaneous Recombinant Interleukin-2 Plus Interferon Alfa-2a for Melanoma Patients With Nonresectable Distant Disease: A Phase I/II Pilot Trial. <i>Annals of Surgical Oncology</i> , 1999, 6, 272-278.	1.5	17
102	Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon α 2a and tamoxifen in metastatic melanoma. <i>Melanoma Research</i> , 1999, 9, 503-510.	1.2	17
103	The prognostic role of the sentinel lymph node in clinically node-negative patients with cutaneous melanoma: experience of the Genoa group. <i>European Journal of Surgical Oncology</i> , 2005, 31, 1191-1197.	1.0	17
104	Interferon alpha for the adjuvant treatment of melanoma: review of international literature and practical recommendations from an expert panel on the use of interferon. <i>Journal of Chemotherapy</i> , 2014, 26, 193-201.	1.5	17
105	Clinical, pathological and dermoscopic phenotype of MITF p.E318K carrier cutaneous melanoma patients. <i>Journal of Translational Medicine</i> , 2020, 18, 78.	4.4	17
106	Circulating tumour DNA and melanoma survival: A systematic literature review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103187.	4.4	17
107	The Multidisciplinary Management of Cutaneous Squamous Cell Carcinoma: A Comprehensive Review and Clinical Recommendations by a Panel of Experts. <i>Cancers</i> , 2022, 14, 377.	3.7	17
108	Merkel cell carcinoma of the skin. Treatment of primary, recurrent, and metastatic disease: review of clinical cases. <i>Anticancer Research</i> , 1997, 17, 673-7.	1.1	17

#	ARTICLE	IF	CITATIONS
109	Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced <i>NRAS</i> - or <i>BRAF</i> -mutated melanoma. <i>Oncotarget</i> , 2019, 10, 1850-1859.	1.8	16
110	CDKN2A germline mutations are not associated with poor survival in an Italian cohort of melanoma patients. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 1263-1271.	1.2	16
111	Response to ipilimumab therapy in metastatic melanoma patients: potential relevance of CTLA-4+ tumor infiltrating lymphocytes and their in situ localization. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 653-662.	4.2	16
112	Data of Italian Cancer Centers from two regions with high incidence of SARS CoV-2 infection provide evidence for the successful management of patients with locally advanced and metastatic melanoma treated with immunotherapy in the era of COVID-19. <i>Seminars in Oncology</i> , 2020, 47, 302-304.	2.2	15
113	Phenotypic characterization of tumor CTLA-4 expression in melanoma tissues and its possible role in clinical response to Ipilimumab. <i>Clinical Immunology</i> , 2020, 215, 108428.	3.2	15
114	Update on Metastatic Uveal Melanoma: Progress and Challenges. <i>BioDrugs</i> , 2016, 30, 161-172.	4.6	14
115	Potential Onco-Suppressive Role of miR122 and miR144 in Uveal Melanoma through ADAM10 and C-Met Inhibition. <i>Cancers</i> , 2020, 12, 1468.	3.7	14
116	PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort. <i>Journal of Translational Medicine</i> , 2021, 19, 270.	4.4	14
117	Cytokines can counteract the inhibitory effect of MEK-i on NK-cell function. <i>Oncotarget</i> , 2016, 7, 60858-60871.	1.8	14
118	Update: current management issues in malignant melanoma. <i>Melanoma Research</i> , 2005, 15, 319-324.	1.2	13
119	Low Levels of Genetic Heterogeneity in Matched Lymph Node Metastases from Patients with Melanoma. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1917-1920.	0.7	13
120	An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system. <i>European Journal of Cancer</i> , 2019, 107, 175-185.	2.8	13
121	Immunological and biological changes during ipilimumab (Ipi) treatment and their correlation with clinical response and survival.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8573-8573.	1.6	13
122	Course of Sars-CoV2 Infection in Patients with Cancer Treated with anti-PD-1: A Case Presentation and Review of the Literature. <i>Cancer Investigation</i> , 2021, 39, 9-14.	1.3	12
123	Merkel Cell Carcinoma: An Immunotherapy Fairy-Tale?. <i>Frontiers in Oncology</i> , 2021, 11, 739006.	2.8	12
124	Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma. <i>Journal of Translational Medicine</i> , 2022, 20, 159.	4.4	12
125	Erythropoietin and granulocyte-macrophage colony-stimulating factor allow acceleration and dose escalation of cyclophosphamide/epidoxorubicin/5-fluorouracil chemotherapy: a dose-finding study in patients with advanced breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1996, 38, 487-494.	2.3	11
126	A Feasibility Study using Polychemotherapy (Cisplatin + Vindesine + Dacarbazine) plus Interferon-Alpha or Monochemotherapy with Dacarbazine plus Interferon-Alpha in Metastatic Melanoma. <i>Tumori</i> , 2001, 87, 219-222.	1.1	11

#	ARTICLE	IF	CITATIONS
127	Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib. <i>Oncotarget</i> , 2018, 9, 12408-12417.	1.8	11
128	An outpatient phase I study of a subcutaneous interleukin-2 and intramuscular alpha-2a-interferon combination in advanced malignancies. <i>Annals of Oncology</i> , 1992, 3, 559-563.	1.2	10
129	Phase II study of vinorelbine and ifosfamide in anthracycline resistant metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 1997, 42, 183-186.	2.5	10
130	Case Report: Immune-Related Toxicity During Adjuvant Treatment With BRAF Plus MEK Inhibitors in a Melanoma Patient. <i>Frontiers in Immunology</i> , 2020, 11, 579523.	4.8	10
131	Predictors of germline status for hereditary melanoma: 5 years of multi-gene panel testing within the Italian Melanoma Intergroup. <i>ESMO Open</i> , 2022, 7, 100525.	4.5	10
132	Mitoxantrone and mitomycin C as second-line treatment for advanced breast cancer. <i>Annals of Oncology</i> , 1992, 3, 165-166.	1.2	9
133	Second-Line Hormonotherapy for Breast Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1993, 16, 522-525.	1.3	9
134	Thymidine Labeling Index Analysis in Early Breast Cancer Patients Randomized to Receive Perioperative Chemotherapy. <i>Oncology</i> , 2001, 60, 88-93.	1.9	9
135	The <i>CDKN2A/p16</i> ^{INK4a} 5'UTR sequence and translational regulation: impact of novel variants predisposing to melanoma. <i>Pigment Cell and Melanoma Research</i> , 2016, 29, 210-221.	3.3	9
136	Italian cohort of ipilimumab expanded access programme (EAP): Efficacy, safety, and correlation with mutation status in metastatic melanoma patients.. <i>Journal of Clinical Oncology</i> , 2013, 31, 9070-9070.	1.6	9
137	Combining molecular and immunohistochemical analyses of key drivers in primary melanomas: interplay between germline and somatic variations. <i>Oncotarget</i> , 2018, 9, 5691-5702.	1.8	9
138	Identifying candidates for immunotherapy with cemiplimab to treat advanced cutaneous squamous cell carcinoma: an expert opinion. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592110662.	3.2	9
139	Melanoma in children and adolescents: analysis of susceptibility genes in 123 Italian patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 213-221.	2.4	8
140	Clinical Significance of Distant Metastasis-Free Survival (DMFS) in Melanoma: A Narrative Review from Adjuvant Clinical Trials. <i>Journal of Clinical Medicine</i> , 2021, 10, 5475.	2.4	8
141	Proliferative, phenotypic and functional and molecular characteristics of tumour-infiltrating lymphocytes obtained from unselected patients with malignant melanomas and expanded in vitro in the presence of recombinant interleukin-2. <i>Melanoma Research</i> , 1994, 4, 127-133.	1.2	7
142	A novel multiplex pyrosequencing assay for genotyping functionally relevant CTLA-4 polymorphisms: Potential applications in autoimmunity and cancer. <i>Human Immunology</i> , 2014, 75, 730-739.	2.4	7
143	Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS). <i>European Journal of Cancer</i> , 2021, 152, 116-128.	2.8	7
144	The NIBIT-M1 trial: Activity of ipilimumab plus fotemustine in patients with melanoma and brain metastases.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8529-8529.	1.6	7

#	ARTICLE	IF	CITATIONS
145	Time to central nervous system (CNS) metastases (mets) with atezolizumab (A) or placebo (P) combined with cobimetinib (C) + vemurafenib (V) in the phase III IMspire150 study.. Journal of Clinical Oncology, 2020, 38, 10023-10023.	1.6	7
146	Merkel cell carcinoma of the skin. Treatment of primary, recurrent and metastatic disease: review of clinical cases. Anticancer Research, 1997, 17, 2339-42.	1.1	7
147	Impact of Irradiation of Residual Breast on Adjuvant Chemotherapy Dose Intensity. American Journal of Clinical Oncology: Cancer Clinical Trials, 1993, 16, 58-60.	1.3	6
148	Vemurafenib in BRAFV600 mutated metastatic melanoma: a subanalysis of the Italian population of a global safety study. Future Oncology, 2015, 11, 1355-1362.	2.4	6
149	Patients with locally advanced and metastatic cutaneous squamous cell carcinoma treated with immunotherapy in the era of COVID-19: stop or go? Data from five Italian referral cancer centers. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592097700.	3.2	6
150	Efficacy of BRAF and MEK Inhibition in Patients with BRAF-Mutant Advanced Melanoma and Germline CDKN2A Pathogenic Variants. Cancers, 2021, 13, 2440.	3.7	6
151	Safety and activity of Combined AVELumab with Axitinib in unresectable or metastatic Thymomas B3 and Thymic carcinomas: The CAVEATT study.. Journal of Clinical Oncology, 2020, 38, e21114-e21114.	1.6	6
152	Sentinel lymph node biopsy in melanoma patients: the medical oncologist's perspective. Journal of Surgical Oncology, 2004, 85, 162-165.	1.7	5
153	Germline <i>MC1R</i> variants and frequency of somatic <i>BRAF</i> , <i>NRAS</i> , and <i>TERT</i> mutations in melanoma: Literature review and meta-analysis. Molecular Carcinogenesis, 2021, 60, 167-171.	2.7	5
154	Avelumab treatment in Italian patients with metastatic Merkel cell carcinoma: experience from an expanded access program. Journal of Translational Medicine, 2021, 19, 70.	4.4	5
155	Phase II multicenter trial of ipilimumab combined with fotemustine in patients with metastatic melanoma: The Italian Network for Tumor Biotherapy (NIBIT)-M1 trial.. Journal of Clinical Oncology, 2012, 30, 8513-8513.	1.6	5
156	Computer graphics as a tool in cytogenetic research and education. Bioinformatics, 1995, 11, 463-468.	4.1	4
157	Predictive role of preoperative lymphoscintigraphy on the status of the sentinel lymph node in clinically node-negative patients with cutaneous melanoma. Melanoma Research, 2009, 19, 243-251.	1.2	4
158	Diagnostic and Therapeutic Approaches in Italian Hospitals: Adjuvant and Metastatic Therapy in Melanoma. Dermatology, 2013, 226, 22-27.	2.1	4
159	EGFR-TKI Plus Anti-Angiogenic Drugs in EGFR-Mutated Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Clinical Trials. JNCI Cancer Spectrum, 2020, 4, pkaa064.	2.9	4
160	Pathological and clinical features of enteric adenocarcinoma of the thymus. A pooled analysis of cases from a reference center and systematic review of the literature. Cancer Treatment Reviews, 2021, 92, 102133.	7.7	4
161	SARS-CoV-2 vaccine in patients with thymic epithelial tumours with and without active or pre-existing autoimmune disorders: Brief report of a TYME network safety analysis. European Journal of Cancer, 2022, 166, 202-207.	2.8	4
162	Chemotherapy in patients with localized angiosarcoma of any site: A retrospective european study. European Journal of Cancer, 2022, 171, 183-192.	2.8	4

#	ARTICLE	IF	CITATIONS
163	Continuous Venous Infusion of Vinblastine in Metastatic Breast Cancer. <i>Chemotherapy</i> , 1991, 37, 146-149.	1.6	3
164	9315 Ipilimumab in pretreated metastatic uveal melanoma patients: safety and clinical efficacy. <i>European Journal of Cancer, Supplement</i> , 2009, 7, 581.	2.2	3
165	Open-label, multicenter safety study of vemurafenib in patients with <i>BRAF</i> ^{V600} mutation-“positive metastatic melanoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 9046-9046.	1.6	3
166	Selective lymph node dissection in patients with intermediate thickness melanoma: our experience. <i>Anticancer Research</i> , 2000, 20, 497-500.	1.1	3
167	Biochemotherapy in metastatic melanoma: quo vadis?. <i>Melanoma Research</i> , 2005, 15, 471-473.	1.2	2
168	New insights in melanoma biology: Running fast towards precision medicine. <i>Seminars in Cancer Biology</i> , 2019, 59, 161-164.	9.6	2
169	Neoadjuvant treatments in patients with high-risk resectable stage III/IV melanoma. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 403-413.	2.4	2
170	The surgical treatment of non-metastatic melanoma in a Clinical National Melanoma Registry Study Group (CNMR): a retrospective cohort quality improvement study to reduce the morbidity rates. <i>BMC Cancer</i> , 2021, 21, 8.	2.6	2
171	Analysis of CTLA-4 gene polymorphisms in patients with advanced melanoma treated with anti-CTLA-4 therapy. <i>Journal of Clinical Oncology</i> , 2011, 29, 8588-8588.	1.6	2
172	Analysis of the proliferative and phenotypic properties of tumor infiltrating lymphocytes expanded in vitro in the course of the clinical trial of adoptive immunotherapy of metastatic melanoma. <i>Oncology Reports</i> , 1997, 4, 27-31.	2.6	2
173	A phase II study evaluating atezolizumab (A), cobimetinib (C), and vemurafenib (V) in patients (pts) with BRAF-mutant melanoma and central nervous system (CNS) metastases (mets). <i>Journal of Clinical Oncology</i> , 2020, 38, TPS10081-TPS10081.	1.6	2
174	Real Life Clinical Management and Survival in Advanced Cutaneous Melanoma: The Italian Clinical National Melanoma Registry Experience. <i>Frontiers in Oncology</i> , 2021, 11, 672797.	2.8	2
175	High Dose Intensity Chemotherapy without Bone Marrow Support: Role of Granulocyte-Macrophage Colony-Stimulating Factor. <i>Annals of the New York Academy of Sciences</i> , 1993, 698, 389-397.	3.8	1
176	Medical treatment of uveal melanoma. <i>Tumori</i> , 2007, 93, suppl 27-30.	1.1	1
177	BREAST-CANCER IN THE ELDERLY - DETECTION AND TREATMENT MODALITIES IN 341 WOMEN. <i>International Journal of Oncology</i> , 1994, 5, 1399-403.	3.3	0
178	Systemic Treatment in Advanced Melanoma. <i>Updates in Surgery Series</i> , 2021, , 167-174.	0.1	0
179	New Melanoma Staging: Prognostic Factors. <i>Updates in Surgery Series</i> , 2021, , 47-53.	0.1	0